Keywords: genentech, sees, sales, leap, eps, rising, still
Genentech sees 2004 sales leap 43% with EPS rising 38%, but still disappoints
Article | 17 January 2005
USA-based Genentech, the biotechnology giant majority-owned by Swiss drug major Roche, saw product sales for full-year 2004 rocket 43% to $3.75 billion and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
